Drug‐induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)

To investigate spontaneous reports of TdP present in the public version of the FDA Adverse Event Reporting System (AERS) in the light of what is already known on their TdP‐liability.

[1]  P. Haddad,et al.  Adverse Effects of Atypical Antipsychotics , 2007, CNS drugs.

[2]  G. Breithardt,et al.  Proarrhythmia as a Class Effect of Quinolones: Increased Dispersion of Repolarization and Triangulation of Action Potential Predict Torsades de Pointes , 2007, Journal of cardiovascular electrophysiology.

[3]  M. Breschi,et al.  Drug‐induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics , 2005, The Journal of pharmacy and pharmacology.

[4]  N. Hartnell,et al.  Replication of the Weber Effect Using Postmarketing Adverse Event Reports Voluntarily Submitted to the United States Food and Drug Administration , 2004, Pharmacotherapy.

[5]  M. Molimard,et al.  Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. , 2004, Toxicology and applied pharmacology.

[6]  L. Rabeneck,et al.  Association of Colonoscopy and Death From Colorectal Cancer , 2009, Annals of Internal Medicine.

[7]  Y. Arbel,et al.  QT prolongation and Torsades de Pointes in patients previously treated with Anthracyclines , 2007, Anti-cancer drugs.

[8]  J. Korvick,et al.  Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Manfred Hauben,et al.  ‘Extreme Duplication’ in the US FDA Adverse Events Reporting System Database , 2007, Drug safety.

[10]  D. Roden,et al.  Unusual Effects of a QT-Prolonging Drug, Arsenic Trioxide, on Cardiac Potassium Currents , 2003, Circulation.

[11]  A. Pariente,et al.  A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. , 2008, British journal of clinical pharmacology.

[12]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[13]  Manfred Hauben,et al.  Illusions of objectivity and a recommendation for reporting data mining results , 2007, European Journal of Clinical Pharmacology.

[14]  T. Nolin,et al.  Antimicrobial-associated QT interval prolongation: pointes of interest. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Dartigues,et al.  Prevalence of cholinesterase inhibitors in subjects with dementia in Europe , 2008, Pharmacoepidemiology and drug safety.

[16]  Peter A Gross,et al.  The FDA and drug safety: a proposal for sweeping changes. , 2006, Archives of internal medicine.

[17]  R. Owens.  Risk Assessment for Antimicrobial Agent‐Induced QTc Interval Prolongation and Torsades de Pointes , 2001, Pharmacotherapy.

[18]  T. Suleyman,et al.  Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil , 2006, Emergency Medicine Journal.

[19]  R. Frothingham,et al.  Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin , 2001, Pharmacotherapy.

[20]  Joseph M. Tonning,et al.  Perspectives on the Use of Data Mining in Pharmacovigilance , 2005, Drug safety.

[21]  M. Scheinman,et al.  Famotidine and long QT syndrome. , 2004, The American journal of cardiology.

[22]  D. Zeltser,et al.  Torsades de pointes induced by antibiotics. , 2006, European journal of internal medicine.

[23]  Signal Detection in the Pharmaceutical Industry , 2007, Drug safety.

[24]  A. Fisher,et al.  Prolonged QT Interval, Syncope, and Delirium with Galantamine , 2008, The Annals of pharmacotherapy.

[25]  P. Schweitzer,et al.  Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes , 2008, Journal of Interventional Cardiac Electrophysiology.

[26]  D. Zeltser,et al.  Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports , 2006, Mycoses.

[27]  Vaishali K. Patadia,et al.  Data Mining in Pharmacovigilance , 2005 .

[28]  G. Bigelow,et al.  QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. , 2007, Archives of internal medicine.

[29]  R. Bergemann,et al.  Economic outcomes after heart valve replacement surgery in Germany , 2001 .

[30]  Shuichi Sato,et al.  Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems. , 2003, European journal of pharmacology.

[31]  R. Woosley,et al.  QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system , 2005, Pharmacoepidemiology and drug safety.

[32]  David A. Kessler.  Introducing MEDWatch: A New Approach to Reporting Medication and Device Adverse Effects and Product Problems , 1993 .

[33]  P. Jonsson,et al.  Use of antipsychotic medications in older home-care patients. Report from nine European countries , 2008, Aging clinical and experimental research.

[34]  P. Rochon,et al.  Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis , 2008, Canadian Medical Association Journal.

[35]  P. Mehler,et al.  Effects of Buprenorphine on Cardiac Repolarization in a Patient with Methadone‐Related Torsade de Pointes , 2005, Pharmacotherapy.

[36]  N. Moore,et al.  Atypical Antipsychotics , 2005, Drug safety.

[37]  S. Hägg,et al.  Drug‐induced torsades de pointes: a review of the Swedish pharmacovigilance database , 2008, Pharmacoepidemiology and drug safety.

[38]  M. Falagas,et al.  Arrhythmias associated with fluoroquinolone therapy. , 2007, International journal of antimicrobial agents.

[39]  D. Wolbrette.  Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. , 2003, The American journal of cardiology.

[40]  B. Darpö,et al.  Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes , 2001 .

[41]  M. Hauben,et al.  Data mining for signals in spontaneous reporting databases: proceed with caution , 2007, Pharmacoepidemiology and drug safety.

[42]  M. Krantz,et al.  Physician Awareness of the Cardiac Effects of Methadone , 2007, Journal of addictive diseases.

[43]  R. Majdzadeh,et al.  Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database , 2007, Pharmacoepidemiology and drug safety.

[44]  R. Leone,et al.  Influence of Regulatory Measures on the Rate of Spontaneous Adverse Drug Reaction Reporting in Italy , 2008, Drug safety.

[45]  A. Pariente,et al.  Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases The Notoriety Bias , 2007, Drug safety.

[46]  A. Bianucci,et al.  Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels. , 2004, Current medicinal chemistry.